



December 05, 2025

To, Listing Department, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Ref: BSE Scrip Code: 544497	To, The National Stock Exchange of India Ltd. The Listing Department Exchange Plaza, Bandra – Kurla Complex, Mumbai – 400051, NSE Scrip Code: AHCL
---	---

**Sub: Outcome of Board Meeting held on December 05, 2025, of Anlon Healthcare Limited.**

Respected Sir/Madam,

Pursuant to Regulations 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the Outcome of Board Meeting of the Company held on Friday, December 05, 2025 at the Registered Office of the Company where the following matters *inter alia* have been considered, approved, and taken on record by the Board of Directors:

- i) Reviewed the ongoing development of the new products Butamirate Citrate and Ketoprofen Lysinate, aimed at strengthening the Company's market position, enhancing revenue diversification, and addressing emerging customer requirements. After deliberations on market opportunities, the development roadmap, estimated project cost, and expected financial implications, the Board approved the initiation of the new product development programme along with the necessary capacity enhancement. The Board also emphasised strict adherence to applicable regulatory requirements, cost discipline, and the approved project timelines.
- ii) Additionally, discussed in detail updates covering operational performance, technology initiatives, customer engagement activities, and the strategic rationale and expected benefits arising from the proposed acquisition of two entities as subsidiaries of the Company. The Board reviewed the updates and advised the management to maintain focus on timely execution across all functional areas.
- iii) Considered and approved the variation in one of the objects of the initial public offering ("IPO") for proposed expansion through inorganic growth and further upgradation.
- iv) Approved and taken on record the Notice of Postal Ballot for passing of Special Resolution of members of the Company to consider and approve the variation in one of the objects of the IPO for proposed expansion through inorganic growth and further upgradation.
- v) Approved the appointment of M/s. K.P. Ghelani & Associates, Practising Company Secretary, as a Scrutinizer to conducting Postal Ballot process and remote e-voting process.

---

**ANLON HEALTHCARE LIMITED**

CIN No.: U24230GJ2013PLC077543

REGISTERED OFFICE: 101/102, Silver Coin Complex, Opp. Crystal Mall, Kalawad Road, Rajkot-360005, Gujarat (INDIA)

PHONE NO.: +91-7069690081/82 | Email: [info@anlonhealthcare.com](mailto:info@anlonhealthcare.com) | [www.anlon.in](http://www.anlon.in)



- vi) Discussed and finalized Friday, December 05, 2025, as the cut-off date for postal ballot notice and remote e- voting process.
- vii) Discussed and finalized remote e-voting period where the voting period commences on Tuesday, December 09, 2025, 09:00 A.M. IST and ends on Wednesday, January 07, 2025, 05:00 P.M. IST.

Meeting Commenced on 01:30 p.m. IST and Concluded on 02:30 p.m. IST.

You are requested to take the above information on your record.

Thanking You.

**For ANLON HEALTHCARE LIMITED**

**PUNITKUMAR RASADIA  
MANAGING DIRECTOR  
DIN: 06696258**

---

**ANLON HEALTHCARE LIMITED**

CIN No.: U24230GJ2013PLC077543

REGISTERED OFFICE: 101/102, Silver Coin Complex, Opp. Crystal Mall, Kalawad Road, Rajkot-360005, Gujarat (INDIA)

PHONE NO.: +91-7069690081/82 | Email: [info@anlonhealthcare.com](mailto:info@anlonhealthcare.com) | [www.anlon.in](http://www.anlon.in)